Persistent Hypokalemic Paralysis in a Patient with Graves’ Disease and Gitelman Syndrome

키워드

참고문헌 (23)

1. Kung AW, "Clinical review : Thyrotoxic periodic paralysis : a diagnostic challenge", J Clin Endocrinol Metab, 91(7), pp.2490~2495 (2006)
2. Ryu S, "Low-dose glucocorticoid can lead to hypokalemic paralysis", Endocrine, 67(2), pp.494~495 (2020)
3. Mizokami T, "Graves' disease and Gitelman syndrome", Clin Endocrinol(Oxf), 84(1), pp.149~150 (2016)
4. Oba T, "A case of Gitelman syndrome that was difficult to distinguish from hypokalemic periodic paralysis caused by Graves' disease", J Nippon Med Sch, 86(5), pp.301~306 (2019)
5. Zha B, "Coexistence of Graves'disease in a 14-year-old young girl with Gitelman syndrome", Clin Endocrinol(Oxf), 83(6), pp.995~997 (2015)
6. Ryan DP, "Mutations in potassium channel Kir2.6cause susceptibility to thyrotoxic hypokalemic periodic paralysis", Cell, 140(1), pp.88~98 (2010)
7. Paninka RM, "Down-regulation of Kir2.6 channel by c-termini mutation D252N and its association with the susceptibility to thyrotoxic periodic paralysis", Neuroscience, 346, pp.197~202 (2017)
8. Rhee EP, "Case records of the Massachusetts General Hospital. Case 4-2012. A 37-year-old man with muscle pain, weakness, and weight loss", N Engl J Med, 366(6), pp.553~560 (2012)
9. Mastroianni N, "Molecular cloning, expression pattern, and chromosomal localization of the human Na-Cl thiazide-sensitive cotransporter(SLC12A3)", Genomics, 35(3), pp.486~493 (1996)
10. Riveira-Munoz E, "Gitelman's syndrome : towards genotype-phenotype correlations?", Pediatr Nephrol, 22(3), pp.326~332 (2007)
11. Melander O, "Genetic variants of thiazide-sensitive NaCl-cotransporter in Gitelman's syndrome and primary hypertension", Hypertension, 36(3), pp.389~394 (2000)
12. Gitelman HJ, "A new familial disorder characterized by hypokalemia and hypomagnesemia", Trans Assoc Am Physicians, 79, pp.221~235 (1966)
13. Simon DB, "Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter", Nat Genet, 12(1), pp.24~30 (1996)
14. Cruz DN, "Mutations in the Na-Cl cotransporter reduce blood pressure in humans", Hypertension, 37(6), pp.1458~1464 (2001)
15. Blanchard A, "Gitelman syndrome: consensus and guidance from a kidney disease: improving global outcomes (KDIGO) controversies conference", Kidney Int, 91(1), pp.24~33 (2017)
16. Hsu YJ, "Heterozygous mutations of the sodium chloride cotransporter in Chinese children : prevalence and association with blood pressure", Nephrol Dial Transplant, 24(4), pp.1170~1175 (2009)
17. Kondo A, "Examination of the predicted prevalence of Gitelman syndrome by ethnicity based on genome databases", Sci Rep, 11(1), pp.16099~ (2021)
18. Cruz DN, "Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life", Kidney Int, 59(2), pp.710~717 (2001)
19. Colussi G, "Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome", Am J Nephrol, 14(2), pp.127~135 (1994)
20. Ito Y, "Eplerenone improved hypokalemia in a patient with Gitelman's syndrome", Intern Med, 51(1), pp.83~86 (2012)
21. Brambilla G, "It is never too late for a genetic disease : a case of a 79-year-old man with persistent hypokalemia", J Nephrol, 26(3), pp.594~598 (2013)
22. Larkins N, "A severe phenotype of Gitelman syndrome with increased prostaglandin excretion and favorable response to indomethacin", Clin Kidney J, 7(3), pp.306~310 (2014)
23. Blanchard A, "Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome", J Am Soc Nephrol, 26(2), pp.468~475 (2015)

관련 논문AI추천